Antonio Giordano, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptor, erbB-2 | 13 | 2024 | 2606 | 1.100 |
Why?
|
Adipose Tissue, White | 3 | 2023 | 371 | 0.920 |
Why?
|
Median Eminence | 1 | 2021 | 28 | 0.770 |
Why?
|
Breast Neoplasms | 25 | 2024 | 21188 | 0.750 |
Why?
|
Oxytocin | 1 | 2022 | 403 | 0.590 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11886 | 0.490 |
Why?
|
Inflammatory Breast Neoplasms | 3 | 2023 | 154 | 0.460 |
Why?
|
Obesity | 12 | 2023 | 13091 | 0.410 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2013 | 957 | 0.380 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2021 | 3554 | 0.350 |
Why?
|
Disease-Free Survival | 7 | 2018 | 6856 | 0.320 |
Why?
|
Body Mass Index | 7 | 2020 | 13055 | 0.300 |
Why?
|
Adipose Tissue, Brown | 4 | 2022 | 776 | 0.300 |
Why?
|
Ketones | 2 | 2021 | 183 | 0.290 |
Why?
|
Furans | 2 | 2021 | 202 | 0.280 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2012 | 755 | 0.280 |
Why?
|
Neoplastic Stem Cells | 2 | 2012 | 1356 | 0.280 |
Why?
|
Paclitaxel | 5 | 2019 | 1735 | 0.280 |
Why?
|
Insulin Resistance | 4 | 2022 | 3982 | 0.270 |
Why?
|
Environmental Pollutants | 1 | 2016 | 1296 | 0.270 |
Why?
|
Cold Temperature | 2 | 2020 | 791 | 0.260 |
Why?
|
Cell Transdifferentiation | 2 | 2024 | 187 | 0.250 |
Why?
|
Adipocytes | 2 | 2024 | 1199 | 0.250 |
Why?
|
Taxoids | 3 | 2018 | 668 | 0.240 |
Why?
|
Energy Metabolism | 6 | 2022 | 2905 | 0.230 |
Why?
|
Adipose Tissue | 8 | 2023 | 3335 | 0.230 |
Why?
|
Cholinergic Agents | 1 | 2023 | 97 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2022 | 12253 | 0.220 |
Why?
|
Sterol Esterase | 1 | 2022 | 39 | 0.210 |
Why?
|
Mice, Obese | 1 | 2023 | 418 | 0.210 |
Why?
|
Thermogenesis | 3 | 2022 | 494 | 0.200 |
Why?
|
Embolism, Fat | 1 | 2022 | 46 | 0.200 |
Why?
|
Glucagon | 1 | 2023 | 535 | 0.180 |
Why?
|
Atlases as Topic | 1 | 2022 | 248 | 0.180 |
Why?
|
PPAR gamma | 1 | 2022 | 487 | 0.170 |
Why?
|
Ghrelin | 1 | 2020 | 251 | 0.160 |
Why?
|
Neoadjuvant Therapy | 3 | 2021 | 2909 | 0.150 |
Why?
|
Leptin | 2 | 2022 | 1597 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2016 | 4926 | 0.150 |
Why?
|
Intra-Abdominal Fat | 2 | 2022 | 625 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5434 | 0.140 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2019 | 1535 | 0.140 |
Why?
|
Treatment Outcome | 14 | 2024 | 65480 | 0.140 |
Why?
|
Epithelial Cells | 2 | 2024 | 3702 | 0.140 |
Why?
|
Adipocytes, Brown | 2 | 2022 | 160 | 0.140 |
Why?
|
Hypothalamus | 1 | 2022 | 1004 | 0.130 |
Why?
|
Adipocytes, White | 2 | 2020 | 92 | 0.130 |
Why?
|
Spermidine | 1 | 2016 | 63 | 0.130 |
Why?
|
Epirubicin | 1 | 2016 | 81 | 0.130 |
Why?
|
Stomach | 1 | 2020 | 702 | 0.130 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 930 | 0.130 |
Why?
|
Middle Aged | 26 | 2024 | 223737 | 0.130 |
Why?
|
Humans | 50 | 2024 | 768970 | 0.130 |
Why?
|
Prognosis | 8 | 2022 | 30046 | 0.120 |
Why?
|
Metabolic Diseases | 1 | 2022 | 684 | 0.120 |
Why?
|
Eating | 1 | 2022 | 1542 | 0.120 |
Why?
|
Lung Diseases, Interstitial | 1 | 2023 | 940 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5342 | 0.110 |
Why?
|
Female | 33 | 2024 | 397515 | 0.110 |
Why?
|
Tryptophan | 1 | 2016 | 482 | 0.110 |
Why?
|
Aged | 20 | 2024 | 171786 | 0.110 |
Why?
|
Italy | 1 | 2016 | 856 | 0.110 |
Why?
|
Receptors, Estrogen | 5 | 2022 | 2252 | 0.110 |
Why?
|
Adult | 21 | 2024 | 223851 | 0.100 |
Why?
|
RNA, Antisense | 1 | 2013 | 136 | 0.100 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13698 | 0.100 |
Why?
|
Mice | 8 | 2024 | 82072 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2020 | 2885 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6547 | 0.100 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13594 | 0.090 |
Why?
|
Piperazines | 2 | 2019 | 2553 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 3518 | 0.090 |
Why?
|
Fasting | 1 | 2017 | 1610 | 0.090 |
Why?
|
Nomograms | 1 | 2013 | 236 | 0.090 |
Why?
|
MicroRNAs | 3 | 2024 | 3811 | 0.090 |
Why?
|
Siberia | 2 | 2020 | 30 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2227 | 0.090 |
Why?
|
Pyridines | 2 | 2019 | 2895 | 0.090 |
Why?
|
Animals | 11 | 2024 | 169335 | 0.080 |
Why?
|
Endothelial Cells | 3 | 2023 | 3592 | 0.080 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11262 | 0.080 |
Why?
|
Endocrine System | 1 | 2010 | 113 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2542 | 0.080 |
Why?
|
Cell Count | 1 | 2012 | 1833 | 0.080 |
Why?
|
Receptor Cross-Talk | 1 | 2008 | 118 | 0.080 |
Why?
|
Blood Glucose | 3 | 2017 | 6435 | 0.070 |
Why?
|
Aminopyridines | 2 | 2023 | 580 | 0.070 |
Why?
|
Receptors, Leptin | 1 | 2008 | 352 | 0.070 |
Why?
|
Androstadienes | 2 | 2019 | 348 | 0.070 |
Why?
|
Cell Adhesion Molecules | 1 | 2012 | 1614 | 0.070 |
Why?
|
Cell Line, Tumor | 5 | 2014 | 17173 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2012 | 5906 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2021 | 59739 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 2001 | 0.060 |
Why?
|
Receptors, Progesterone | 2 | 2019 | 1159 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2014 | 8664 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 2960 | 0.060 |
Why?
|
Survival Rate | 2 | 2016 | 12873 | 0.050 |
Why?
|
Anthropometry | 2 | 2020 | 1345 | 0.050 |
Why?
|
Carcinoma | 1 | 2014 | 2340 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9213 | 0.050 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2023 | 69 | 0.050 |
Why?
|
Mammary Glands, Animal | 1 | 2024 | 273 | 0.050 |
Why?
|
Hyalin | 1 | 2022 | 35 | 0.050 |
Why?
|
Models, Biological | 2 | 2024 | 9499 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12562 | 0.050 |
Why?
|
Breast | 2 | 2023 | 1976 | 0.050 |
Why?
|
Lipolysis | 1 | 2022 | 211 | 0.050 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1093 | 0.050 |
Why?
|
Cytochrome P-450 CYP2E1 | 1 | 2020 | 41 | 0.050 |
Why?
|
Retinal Dehydrogenase | 1 | 2020 | 78 | 0.040 |
Why?
|
Fatty Acid Transport Proteins | 1 | 2020 | 31 | 0.040 |
Why?
|
Glucose | 2 | 2023 | 4352 | 0.040 |
Why?
|
Triazines | 1 | 2022 | 311 | 0.040 |
Why?
|
Carnitine O-Palmitoyltransferase | 1 | 2020 | 82 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 374 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 3608 | 0.040 |
Why?
|
Rodentia | 1 | 2022 | 262 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2024 | 1342 | 0.040 |
Why?
|
Male | 10 | 2023 | 365203 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2023 | 566 | 0.040 |
Why?
|
Morpholines | 1 | 2022 | 584 | 0.040 |
Why?
|
Acetates | 1 | 2020 | 317 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2024 | 803 | 0.040 |
Why?
|
Drug Interactions | 1 | 2023 | 1418 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2020 | 278 | 0.040 |
Why?
|
Obesity, Abdominal | 1 | 2022 | 375 | 0.040 |
Why?
|
Stem Cells | 1 | 2012 | 3539 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 60131 | 0.040 |
Why?
|
Immunohistochemistry | 4 | 2015 | 11116 | 0.040 |
Why?
|
Inflammation | 3 | 2022 | 10868 | 0.040 |
Why?
|
Organoids | 1 | 2024 | 745 | 0.040 |
Why?
|
Pericardium | 1 | 2022 | 679 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2021 | 81903 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2024 | 1156 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2022 | 847 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2013 | 10486 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2007 | 2487 | 0.030 |
Why?
|
Disease Progression | 4 | 2020 | 13674 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 640 | 0.030 |
Why?
|
Cisplatin | 1 | 2022 | 1661 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15661 | 0.030 |
Why?
|
Purines | 1 | 2019 | 615 | 0.030 |
Why?
|
Postmenopause | 2 | 2019 | 2519 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2020 | 19023 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 367 | 0.030 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2023 | 1248 | 0.030 |
Why?
|
Gastrectomy | 1 | 2020 | 693 | 0.030 |
Why?
|
Fatty Acids | 1 | 2023 | 1812 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1151 | 0.030 |
Why?
|
Cell Separation | 1 | 2020 | 1728 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2013 | 5196 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22389 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 2055 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 864 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2020 | 1820 | 0.030 |
Why?
|
rhoB GTP-Binding Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39394 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1855 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Cohort Studies | 1 | 2016 | 41808 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2464 | 0.030 |
Why?
|
Galactosides | 1 | 2012 | 54 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2016 | 683 | 0.020 |
Why?
|
Medical Oncology | 1 | 2024 | 2350 | 0.020 |
Why?
|
Adiposity | 1 | 2022 | 1895 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2359 | 0.020 |
Why?
|
Palliative Care | 1 | 2007 | 3644 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 9264 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2020 | 2431 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2020 | 2403 | 0.020 |
Why?
|
Lipids | 1 | 2022 | 3345 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8748 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 615 | 0.020 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2011 | 146 | 0.020 |
Why?
|
Immediate-Early Proteins | 1 | 2013 | 444 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10765 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2016 | 1197 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22296 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9618 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2666 | 0.020 |
Why?
|
Pericytes | 1 | 2012 | 299 | 0.020 |
Why?
|
Weight Loss | 1 | 2020 | 2721 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2012 | 2560 | 0.020 |
Why?
|
Overweight | 1 | 2020 | 2448 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3629 | 0.020 |
Why?
|
Mice, SCID | 1 | 2013 | 2631 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 10400 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6610 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5707 | 0.020 |
Why?
|
Cadherins | 1 | 2012 | 906 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2022 | 14484 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2013 | 1120 | 0.020 |
Why?
|
Transcription Factors | 2 | 2020 | 12174 | 0.020 |
Why?
|
Macrophages | 1 | 2022 | 5801 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4124 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4592 | 0.020 |
Why?
|
Anthracyclines | 1 | 2008 | 286 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 5033 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 6131 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5763 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 1373 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3621 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2007 | 410 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 2460 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11230 | 0.010 |
Why?
|
Indoles | 1 | 2012 | 1836 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2011 | 2414 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12095 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10099 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5793 | 0.010 |
Why?
|
Cell Lineage | 1 | 2012 | 2576 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2812 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2008 | 1750 | 0.010 |
Why?
|
Deoxycytidine | 1 | 2007 | 888 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2008 | 2525 | 0.010 |
Why?
|
Prednisone | 1 | 2007 | 1567 | 0.010 |
Why?
|
Diphosphonates | 1 | 2007 | 634 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10115 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2483 | 0.010 |
Why?
|
Antigens, CD | 1 | 2012 | 4032 | 0.010 |
Why?
|
Imidazoles | 1 | 2007 | 1169 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2012 | 8144 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 13021 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26395 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4862 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9621 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2007 | 3629 | 0.010 |
Why?
|
Pain Measurement | 1 | 2007 | 3586 | 0.010 |
Why?
|
Protein Binding | 1 | 2008 | 9344 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23786 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15471 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16731 | 0.010 |
Why?
|
Prospective Studies | 1 | 2011 | 54962 | 0.000 |
Why?
|
Risk Assessment | 1 | 2007 | 24333 | 0.000 |
Why?
|
Risk Factors | 1 | 2008 | 74976 | 0.000 |
Why?
|